Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens

Senni, Michele; McMurray, John; Wachter, Rolf; McIntyre, Hugh; Reyes, Antonio; Majercak, Ivan; Andreka, Peter; Shehova-Yankova, Nina; Anand, Inder; Yilmaz, Mehmet; Gogia, Harinder; Martinez-Selles, Manuel; Fischer, Steffen; Zilahi, Zsolt; Cosmi, Franco; Gelev, Valeri; Galve, Enrique; Gomez-Doblas, Juanjo; Nociar, Jan; Radomska, Maria; Sokolova, Beata; Volterrani, Maurizio; Sarkar, Arnab; Reimund, Bernard; Chen, Fabian; Charney, Alan

doi:10.1002/ejhf.548

Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens

Atıf İçin Kopyala

Senni M., McMurray J. J. V. , Wachter R., McIntyre H. F. , Reyes A., Majercak I., ...Daha Fazla

EUROPEAN JOURNAL OF HEART FAILURE, cilt.18, sa.9, ss.1193-1202, 2016 (SCI İndekslerine Giren Dergi)

Cilt numarası: 18 Konu: 9
Basım Tarihi: 2016
Doi Numarası: 10.1002/ejhf.548
Dergi Adı: EUROPEAN JOURNAL OF HEART FAILURE
Sayfa Sayıları: ss.1193-1202

Özet

AimsTo assess the tolerability of initiating/uptitrating sacubitril/valsartan (LCZ696) from 50 to 200 mg twice daily (target dose) over 3 and 6 weeks in heart failure (HF) patients (ejection fraction 35%).